Osteosarcoma Market is Set to Rise by 2036 as 8 Emerging Therapies Set to Drive Future Growth

The osteosarcoma treatment pipeline is gradually expanding, with emerging therapies such as OST-HER2 (OS Therapies), DANYELZA (naxitamab-gqgk; SERB Pharmaceutical), Vactosertib (MedPacto), Risvutatug rezetecan (GSK), Olaparib with Ceralaserti (AstraZeneca), OMO-103 (Peptomyc), Eflornithine (DFMO) and AMXT 1501 (Aminex Therapeutics), PEEL-224 (Peel Therapeutics), ADCE-D01 (ADCendo), Dendritic cell-based vaccine (CellxLife), LNTH-2403 (Lantheus), and other investigational agents representing promising assets that could reshape the future treatment landscape, particularly in relapsed and metastatic settings.

LAS VEGAS, Sept. 3, 2026 /PRNewswire/ -- Osteosarcoma treatment typically involves a multimodal approach combining surgical tumor removal with systemic chemotherapy and, in selected patients, radiotherapy. Current treatment recommendations include established chemotherapy agents such as methotrexate, doxorubicin, cisplatin, and ifosfamide. For individuals experiencing relapsed, refractory, or metastatic disease, available second-line approaches include high-dose ifosfamide, etoposide, regorafenib, sorafenib, radium-223 dichloride, and everolimus.

Despite these options, the treatment landscape continues to face substantial unmet needs because only a limited number of therapies are specifically approved for osteosarcoma. In the United States, levoleucovorin (KHAPZORY) has received FDA approval, while mifamurtide (MEPACT) is approved by the European Commission for use across the European Union.

Find out the major differences between osteosarcoma vs Ewing sarcoma @ https://www.delveinsight.com/report-store/osteosarcoma-market

Emerging Osteosarcoma Therapies and Changing Treatment Landscape

The osteosarcoma pipeline is increasingly shifting toward precision medicine, immunotherapy, targeted approaches, and antibody-drug conjugates. Prominent candidates include OST-HER2, a HER2-directed cellular immunotherapy designed to activate tumor-specific immune responses; naxitamab-gqgk (DANYELZA), which recognizes GD2-expressing cancer cells; Vactosertib, which inhibits TGF-β signaling involved in tumor progression and metastasis; and Risvutatug Rezetecan, an ADC developed to deliver cytotoxic activity directly to cancer cells.

However, much of the pipeline remains concentrated in early clinical development, particularly Phase II trials. The limited number of late-stage studies means that substantial randomized evidence demonstrating improvements in overall survival, event-free survival, and durable responses remains unavailable. This evidence gap can delay regulatory progress and contribute to differences in treatment access across major markets.

According to oncology experts at DelveInsight, continued investment in targeted therapies, immunotherapies, tyrosine kinase inhibitors, and cell-based treatment strategies could broaden therapeutic options for patients with difficult-to-treat osteosarcoma.

Osteosarcoma Market Outlook Through 2036

DelveInsight estimates that the osteosarcoma market across the seven major markets—the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan—was worth approximately USD 60 million in 2025. The market is forecast to grow at a CAGR of 9% through 2036.

Growth is expected to be supported by increasing research and development investment, the introduction of novel targeted therapies, improvements in multimodal treatment strategies, and greater focus on relapsed, metastatic, and treatment-resistant disease.

OS Therapies' OST-HER2

HER2-targeted cancer vaccine

OST-HER2 is an investigational HER2-targeted immunotherapy being developed for HER2-expressing cancers, including osteosarcoma. The therapy is designed to activate HER2-specific T cells and encourage the immune system to identify and destroy malignant cells. Following administration, the vector is taken up by antigen-presenting cells, which subsequently stimulate a targeted immune response.

Research, including studies involving canine osteosarcoma, has indicated potential benefits in reducing recurrence and metastatic progression. OST-HER2 is currently being studied as a second-line treatment in a Phase IIb trial, with OS Therapies planning to pursue a BLA through the FDA Accelerated Approval pathway.

In August 2026, OS Therapies announced that the FDA had accepted its request for a Type C Statistical Methods meeting to discuss 2.5-year overall survival data from the Phase IIb study. The company also anticipated reporting interim three-year overall survival data in September 2026. Earlier in March 2026, the EMA's Committee for Advanced Therapies granted OST-HER2 ATMP designation for pulmonary recurrence in resected osteosarcoma. The therapy has also received Fast Track and Orphan Drug designations in the United States.

The osteosarcoma market is expected to evolve gradually, with OST-HER2 projected to emerge as a potential key asset, generating approximately USD 37 million across the 7MM by 2036, as per Thakur.

Iterion Therapeutics' Tegavivint

TBL1X protein inhibitors

Tegavivint is designed to inhibit TBL1, an important co-activator involved in Wnt-mediated gene transcription. By targeting this mechanism, the therapy aims to suppress β-catenin-driven oncogenic activity while potentially avoiding some toxicities associated with upstream Wnt inhibition.

The candidate is being evaluated in combination with gemcitabine in pediatric patients with relapsed or refractory osteosarcoma. It has received Orphan Drug Designation and Rare Pediatric Disease Designation, with topline results expected in the second half of 2027. In February 2026, Iterion announced that the first patient had been dosed in the clinical study sponsored by Emory University and conducted at Children's Healthcare of Atlanta.

Discover more about the new treatment options for osteosarcoma @ Osteosarcoma Bone Cancer - https://www.delveinsight.com/sample-request/osteosarcoma-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

SERB Pharmaceutical's DANYELZA

Antibody-dependent cell cytotoxicity (ADCC)